[Research progression on complement regulatory proteins CD46, CD55, and CD59 in tumor immunotherapy].
Immunologic mechanism of tumor escaping from complements' attack was unclear in the past. The efficacy of immunotherapy, especially humoral immunotherapy, to tumor is unsatisfactory. At present, with the progression in immunology, various tumors were found to highly express one or several kinds of complement regulatory proteins, such as CD46/MCP, CD55/DAF, and CD59/potectin. Complement system of the organism is inhibited because of high expression of complement regulatory proteins; therefore, the tumor can escape from the attack of complement system. Recently, the mechanism of complement regulatory proteins expressing in tumor has been studied in deep; some immunotherapies aim directly at complement regulatory proteins, including monoclonal antibody of complement regulatory proteins and cytokines, have been applied to animal experiments and clinical trails, and got some success. This review elucidated the progression on complement regulatory proteins in tumor immunotherapy.
Qin
Cheng
C
Department of Minimally Invasive Surgery, The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, 530007, P. R. China.
Cai
Xiao-Yong
XY
D000818:Animals; D018958:CD55 Antigens / Q000378:metabolism* / Q000502:physiology; D018957:CD59 Antigens / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D007167:Immunotherapy; D015847:Interleukin-4 / Q000494:pharmacology; D051916:Membrane Cofactor Protein / Q000378:metabolism* / Q000502:physiology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
D018958:CD55 Antigens; D018957:CD59 Antigens; D051916:Membrane Cofactor Protein; D015847:Interleukin-4